• search
Country
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
In vitro Genotoxicity Testing Services

In vitro Genotoxicity Testing Services

Aurigene is committed to provide rapid and solution driven in vitro Genotoxicity testing services.

Genotoxicity is an adverse effect of a chemical on genetic material via variety of mechanisms, including mutation. Genotoxicity testing is very crucial to determine potential carcinogenic or mutagenic compounds that can cause genetic alterations in somatic or germ cells, and this information is used in regulatory decision-making. Mutagenicity (gene mutation and structural and numerical chromosomal alterations) is one of the six basic testing areas that have been adopted by the Organization for Economic Co-operation and Development (OECD, 2011) as the minimum requirement to screen high-production volume chemicals for toxicity.

Speak to our experts

Three Major Endpoints of Genetic Damage

  • Gene mutation (i.e. point mutations or deletions or insertions that affect single or blocks of genes)
  • Clastogenicity (i.e. structural chromosome changes)
  • Aneuploidy (i.e. the occurrence of one or more extra or missing chromosomes, leading to an unbalanced chromosome complement).

In vitro Genotoxicity Testing

  • Bacterial reverse mutation test (OECD 471)
  • In vitro chromosomal aberration test using human blood lymphocytes (OECD 473)
  • In vitro micronucleus test using human blood lymphocytes (OECD 487)
  • Mammalian cell gene mutation assay (OECD 490)

Why Aurigene Pharmaceutical Services?

Combination of tests to assess genetic damage

State-of-the-art facilities

Virtual Tour

 

Contact Us

Country
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
resourceMainImage

JUNE 28, 2022

Neoantigen Specific T cells For Cancer Immunotherapy

Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...

Read More
resourceMainImage

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...

Read More
resourceMainImage

Technology meets sustainability - How a complex API development process goes green

We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...

Read More

Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug

2023

Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack